Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis | Zendy

Alexy Inciarte | Zendy; Lorna Leal | Zendy; Eric Ortega González | Zendy; Agathe León | Zendy; Claudia Lucero | Zendy; Josep Mallolas | Zendy; Berta Torres | Zendy; Montserrat Laguno | Zendy; R. Domínguez | Zendy; Marı́a Martı́nez-Rebollar | Zendy; Ana González-Cordón | Zendy; Anna Cruceta | Zendy; J.A. Arnaiz | Zendy; José M. Gatell | Zendy; Felipe García | Zendy; Eva González Ortega | Zendy; Constanza Lucero | Zendy; José Luís Blanco | Zendy; Estebán Martínez | Zendy; Josep M. Miró | Zendy; Monserrat Laguno | Zendy; Jhon Rojas | Zendy; Christian Manzardo | Zendy; Cristina de la Calle | Zendy; Gerard Espinosa | Zendy; Joan Albert Arnáiz | Zendy; Juan M. Pericàs | Zendy; David Nicolás | Zendy; Marta Bodro | Zendy; Ana del Rı́o | Zendy; Celia Cardozo | Zendy

Open Access

Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis

Author(s) -

Alexy Inciarte,

Lorna Leal,

Eric Ortega González,

Agathe León,

Claudia Lucero,

Josep Mallolas,

Berta Torres,

Montserrat Laguno,

R. Domínguez,

Marı́a Martı́nez-Rebollar,

Ana González-Cordón,

Anna Cruceta,

J.A. Arnaiz,

José M. Gatell,

Felipe García,

Eva González Ortega,

Constanza Lucero,

José Luís Blanco,

Estebán Martínez,

Josep M. Miró,

Monserrat Laguno,

Jhon Rojas,

Christian Manzardo,

Cristina de la Calle,

Gerard Espinosa,

Joan Albert Arnáiz,

Juan M. Pericàs,

David Nicolás,

Marta Bodro,

Ana del Rı́o,

Celia Cardozo

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx246

Subject(s) - cobicistat , elvitegravir , emtricitabine , ritonavir , medicine , lopinavir , regimen , virology , human immunodeficiency virus (hiv) , pharmacology , pre exposure prophylaxis , viral load , antiretroviral therapy , men who have sex with men , syphilis

To assess HIV-1 post-exposure prophylaxis (PEP) non-completion at day 28, comparing ritonavir-boosted lopinavir versus cobicistat-boosted elvitegravir as a single-tablet regimen (STR), using tenofovir disoproxil fumarate/emtricitabine with both of these therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research